Previous 10 | Next 10 |
THE WOODLANDS, Texas, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that the Office of New Drugs of the U.S. Food and Drug Administration (FDA) has reiterated the FDA's prior position and denied Lexicon's appeal of the Complete Response ...
Lexicon Pharmaceuticals ( LXRX ) is now in a “hurry up and wait” limbo, as the company waits for clarity on its dispute resolution petition with the FDA regarding Zynquista in Type 1 diabetes and as investors wait for more information and clarity on the clinical profile of Zynq...
It's been a rough year for Lexicon Pharmaceuticals (NASDAQ: LXRX) . In fact, it's been a rough five years for the pharmaceutical stock, which has lost 49% in that span. The business has struggled to generate much momentum for its lone drug product, Xermelo, a treatment for carcinoid syndrome...
Gainers: LXRX +2.5% . CLNY +2.3% . VMW +1.7% . UPLD +1.5% . OXLC +1.5% . More news on: Lexicon Pharmaceuticals, Inc., Colony Capital, Inc., VMware, Inc., Stocks on the move, Read more ...
Lexicon Pharmaceuticals, Inc (LXRX) Q3 2019 Earnings Conference Call November 7, 2019 08:00 ET Company Participants Lonnel Coats - President and Chief Executive Officer Alex Santini - Executive Vice President and Chief Commercial Officer Dr. Pablo Lapuerta - Executive Vice Presid...
Image source: The Motley Fool. Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Q3 2019 Earnings Call Nov 7, 2019 , 8:00 a.m. ET Operator Continue reading
Lexicon Pharmaceuticals ( LXRX +3.9% ) Q3 results : More news on: Lexicon Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Livongo Health (NASDAQ: LVGO ) +22% after Q3 results . More news on: Livongo Health, Inc., DexCom, Inc., InflaRx N.V., Stocks on the move, Read more ...
Lexicon Pharmaceuticals (NASDAQ: LXRX ): Q3 GAAP EPS of $1.95 beats by $1.41 . Revenue of $294.4M (+4105.7% Y/Y) beats by $282.4M . Press Release More news on: Lexicon Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
THE WOODLANDS, Texas, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended September 30, 2019. “We continue to make good progress on our XERMELO business, with...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Lonnel Coats has prov...
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will release its first quarter 2024 financi...
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats has provided notice of his retirement as chief executive officer and as a member of its board of directors, in each case effective July 7, 2024, his 10th...